A Dose Finding Study of CycloSam® (153-Sm-DOTMP) to Treat Solid Tumor(s) in the Bone or Metastatic to the Bone (Metastatic Prostate, Breast, and Lung, Osteosarcoma, Ewing's Sarcoma, and Other Solid Tumor(s) to the Bone All Eligible)
Latest Information Update: 23 Apr 2025
At a glance
- Drugs Samarium 153 DOTMP (Primary)
- Indications Bone cancer; Bone metastases; Breast cancer; Ewing's sarcoma; Lung cancer; Osteosarcoma; Prostate cancer; Solid tumours
- Focus Adverse reactions
- Sponsors QSAM Biosciences; Telix Pharmaceuticals
Most Recent Events
- 25 Aug 2023 New trial record